{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:52:43Z","timestamp":1791265963112,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prostate cancer (PCa) exhibits an immune \u201ccold\u201d tumor microenvironment (TME) with significant enrichment of immunosuppressive myeloid-derived suppressor cells (MDSCs), which contribute to tumor progression and poor responses to immune checkpoint blockade (ICB). Although extensively studied, the precise mechanism underlying the tumor-intrinsic signals that educate and sustain the expansion and immunosuppressive function of MDSCs remains unelucidated. Here, we identify a previously unrecognized function of RelB by which nuclear interaction with ILF2 restricts ubiquitin-mediated degradation and sustains nuclear stability of RelB, thereby enhancing RelB-mediated\n                    <jats:italic>CSF2<\/jats:italic>\n                    transactivation and enhanced GM-CSF (granulocyte-macrophage colony-stimulating factor) production and secretion. The secreted GM-CSF, in turn, promotes RelB nuclear accumulation, forming a feed-forward loop for sustaining GM-CSF generation. In MDSCs, GM-CSF activates STAT3-mediated MDSC expansion and immunosuppression. Disruption of RelB\/ILF2 complex attenuates GM-CSF-driven MDSC expansion, restores CD8\u207a T cell-mediated antitumor activity, and inhibits tumor growth. In addition, a RelB-targeting peptide SN52 sensitizes PCa tumors to PD-1 blockade therapy. Collectively, our findings identify the RelB\/ILF2\u2013GM-CSF loop as a central regulator of MDSC-mediated immunosuppression, which may be targeted to improve PCa response to ICB.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-09098-x","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:58:03Z","timestamp":1783767483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RelB\/ILF2\u2013GM-CSF loop sustains tumor\u2013MDSC communication in prostate cancer immunosuppression"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8751-3364","authenticated-orcid":false,"given":"Fan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-9171","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-0046","authenticated-orcid":false,"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-1471","authenticated-orcid":false,"given":"Zhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangjun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-9675","authenticated-orcid":false,"given":"Jian Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-1136","authenticated-orcid":false,"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4596-1481","authenticated-orcid":false,"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"9098_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"9098_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"9098_CR3","first-page":"360","volume":"72","author":"VN Giri","year":"2022","unstructured":"Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME. Genetic testing in prostate cancer management: considerations informing primary care. CA Cancer J Clin. 2022;72:360\u201371.","journal-title":"CA Cancer J Clin"},{"key":"9098_CR4","first-page":"245","volume":"67","author":"MK Buyyounouski","year":"2017","unstructured":"Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:245\u201353.","journal-title":"CA Cancer J Clin"},{"key":"9098_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","volume":"23","author":"L Chaiswing","year":"2018","unstructured":"Chaiswing L, Weiss HL, Jayswal RD, Clair DKS, Kyprianou N. Profiles of radioresistance mechanisms in prostate cancer. Crit Rev Oncog. 2018;23:39\u201367.","journal-title":"Crit Rev Oncog"},{"key":"9098_CR6","first-page":"457","volume":"13","author":"F Crowley","year":"2021","unstructured":"Crowley F, Sterpi M, Buckley C, Margetich L, Handa S, Dovey Z. A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer. Res Rep Urol. 2021;13:457\u201372.","journal-title":"Res Rep Urol"},{"key":"9098_CR7","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-20-1682","volume":"26","author":"CM Armstrong","year":"2020","unstructured":"Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, et al. Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer. Clin Cancer Res. 2020;26:6064\u201374.","journal-title":"Clin Cancer Res"},{"key":"9098_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56\u201361.","journal-title":"Science"},{"key":"9098_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34871-9","volume":"13","author":"N Li","year":"2022","unstructured":"Li N, Liu Q, Han Y, Pei S, Cheng B, Xu J, et al. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat Commun. 2022;13:7281.","journal-title":"Nat Commun"},{"key":"9098_CR10","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1016\/j.csbj.2021.08.046","volume":"19","author":"BB Lin","year":"2021","unstructured":"Lin BB, Lei HQ, Xiong HY, Fu X, Shi F, Yang XW, et al. MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. Comput Struct Biotechnol J. 2021;19:4941\u201353.","journal-title":"Comput Struct Biotechnol J"},{"key":"9098_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"9098_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395\u2013405.","journal-title":"J Clin Oncol"},{"key":"9098_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","volume":"78","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur Urol. 2020;78:822\u201330.","journal-title":"Eur Urol"},{"key":"9098_CR14","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1038\/d41586-022-02861-y","volume":"609","author":"A King","year":"2022","unstructured":"King A. Could immunotherapy finally break through in prostate cancer? Nature. 2022;609:S42\u20134.","journal-title":"Nature"},{"key":"9098_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/pcan.2015.39","volume":"18","author":"AM Martin","year":"2015","unstructured":"Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325\u201332.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"9098_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40\u20137.","journal-title":"J Clin Oncol"},{"key":"9098_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"9098_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2022.101668","volume":"61\u201364","author":"N Tumino","year":"2022","unstructured":"Tumino N, Fiore PF, Pelosi A, Moretta L, Vacca P. Myeloid derived suppressor cells in tumor microenvironment: interaction with innate lymphoid cells. Semin Immunol. 2022;61\u201364:101668.","journal-title":"Semin Immunol"},{"key":"9098_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","volume":"40","author":"RJ Tesi","year":"2019","unstructured":"Tesi RJ. MDSC; the most important cell you have never heard of. Trends Pharm Sci. 2019;40:4\u20137.","journal-title":"Trends Pharm Sci"},{"key":"9098_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40425-014-0031-3","volume":"2","author":"SJ Santegoets","year":"2014","unstructured":"Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer. 2014;2:31.","journal-title":"J Immunother Cancer"},{"key":"9098_CR21","doi-asserted-by":"crossref","unstructured":"Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells 2020;9:561\u201389.","DOI":"10.3390\/cells9030561"},{"key":"9098_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s43018-021-00227-3","volume":"2","author":"ZA Lopez-Bujanda","year":"2021","unstructured":"Lopez-Bujanda ZA, Haffner MC, Chaimowitz MG, Chowdhury N, Venturini NJ, Patel RA, et al. Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nat Cancer. 2021;2:803\u201318.","journal-title":"Nat Cancer"},{"key":"9098_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363\u20139.","journal-title":"Nature"},{"key":"9098_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nri.2017.142","volume":"18","author":"K Taniguchi","year":"2018","unstructured":"Taniguchi K, Karin M. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309\u201324.","journal-title":"Nat Rev Immunol"},{"key":"9098_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.celrep.2014.08.049","volume":"9","author":"DJ Wang","year":"2014","unstructured":"Wang DJ, Ratnam NM, Byrd JC, Guttridge DC. NF-\u03baB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. Cell Rep. 2014;9:90\u2013103.","journal-title":"Cell Rep"},{"key":"9098_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03966-7","volume":"9","author":"M Taki","year":"2018","unstructured":"Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun. 2018;9:1685.","journal-title":"Nat Commun"},{"key":"9098_CR27","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2023.04.019","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, Dou X, Chen S, Yu X, Huang X, Zhang L, et al. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023;41:1294\u2013308.e1298.","journal-title":"Cancer Cell"},{"key":"9098_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1189\/jlb.0513305","volume":"94","author":"P Millet","year":"2013","unstructured":"Millet P, McCall C, Yoza B. RelB: an outlier in leukocyte biology. J Leukoc Biol. 2013;94:941\u201351.","journal-title":"J Leukoc Biol"},{"key":"9098_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53112-9","volume":"15","author":"AL Geiselhoringer","year":"2024","unstructured":"Geiselhoringer AL, Kolland D, Patt AJ, Hammann L, Kohler A, Kreft L, et al. Dominant immune tolerance in the intestinal tract imposed by RelB-dependent migratory dendritic cells regulates protective type 2 immunity. Nat Commun. 2024;15:9143.","journal-title":"Nat Commun"},{"key":"9098_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/373531a0","volume":"373","author":"L Burkly","year":"1995","unstructured":"Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature. 1995;373:531\u20136.","journal-title":"Nature"},{"key":"9098_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1178446","volume":"10","author":"J Wu","year":"2023","unstructured":"Wu J, Yu X, Zhu H, Chen P, Liu T, Yin R, et al. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer. Front Mol Biosci. 2023;10:1178446.","journal-title":"Front Mol Biosci"},{"key":"9098_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13046-018-0849-5","volume":"37","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xu Z, Ding J, Tan C, Hu W, Li Y, et al. HZ08 suppresses RelB-activated MnSOD expression and enhances radiosensitivity of prostate cancer cells. J Exp Clin Cancer Res. 2018;37:174.","journal-title":"J Exp Clin Cancer Res"},{"key":"9098_CR33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-022-02243-2","volume":"41","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhu S, Du Y, Xu F, Sun W, Xu Z, et al. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J Exp Clin Cancer Res. 2022;41:66.","journal-title":"J Exp Clin Cancer Res"},{"key":"9098_CR34","first-page":"3181","volume":"7","author":"N Chi","year":"2014","unstructured":"Chi N, Tan Z, Ma K, Bao L, Yun Z. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med. 2014;7:3181\u201392.","journal-title":"Int J Clin Exp Med"},{"key":"9098_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54364-1","volume":"15","author":"A Kiviaho","year":"2024","unstructured":"Kiviaho A, Eerola SK, Kallio HML, Andersen MK, Hoikka M, Tiihonen AM, et al. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat Commun. 2024;15:9949.","journal-title":"Nat Commun"},{"key":"9098_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/aja.2008.44","volume":"11","author":"SQ Yu","year":"2009","unstructured":"Yu SQ, Lai KP, Xia SJ, Chang HC, Chang C, Yeh S. The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl. 2009;11:39\u201348.","journal-title":"Asian J Androl"},{"key":"9098_CR37","doi-asserted-by":"crossref","unstructured":"Staal J, Beyaert R. Inflammation and NF-\u03baB signaling in prostate cancer: mechanisms and clinical implications. Cells 2018;7:122\u201341.","DOI":"10.3390\/cells7090122"},{"key":"9098_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tips.2018.10.008","volume":"40","author":"RJ Tesi","year":"2019","unstructured":"Tesi RJ. MDSC; the Most Important Cell You Have Never Heard Of. Trends Pharmacol Sci. 2019;40:4\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"9098_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know. Cell Res. 2006;16:126\u201333.","journal-title":"Cell Res"},{"key":"9098_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"9098_CR41","doi-asserted-by":"publisher","first-page":"e1344804","DOI":"10.1080\/2162402X.2017.1344804","volume":"6","author":"AA Al-Khami","year":"2017","unstructured":"Al-Khami AA, Zheng L, Del Valle L, Hossain F, Wyczechowska D, Zabaleta J, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology. 2017;6:e1344804.","journal-title":"Oncoimmunology"},{"key":"9098_CR42","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/08830180600992498","volume":"25","author":"KM Hege","year":"2006","unstructured":"Hege KM, Jooss K, Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol. 2006;25:321\u201352.","journal-title":"Int Rev Immunol"},{"key":"9098_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1165\/rcmb.2013-0114OC","volume":"50","author":"K Yamamoto","year":"2014","unstructured":"Yamamoto K, Ahyi AN, Pepper-Cunningham ZA, Ferrari JD, Wilson AA, Jones MR, et al. Roles of lung epithelium in neutrophil recruitment during pneumococcal pneumonia. Am J Respir Cell Mol Biol. 2014;50:253\u201362.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"9098_CR44","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1074\/jbc.M110.119438","volume":"286","author":"CY Sasaki","year":"2011","unstructured":"Sasaki CY, Ghosh P, Longo DL. Recruitment of RelB to the Csf2 promoter enhances RelA-mediated transcription of granulocyte-macrophage colony-stimulating factor. J Biol Chem. 2011;286:1093\u2013102.","journal-title":"J Biol Chem"},{"key":"9098_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/JLB.4RU0819-150RR","volume":"107","author":"MJ Sanaei","year":"2020","unstructured":"Sanaei MJ, Salimzadeh L, Bagheri N. Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in prostate cancer. J Leukoc Biol. 2020;107:43\u201356.","journal-title":"J Leukoc Biol"},{"key":"9098_CR46","doi-asserted-by":"crossref","unstructured":"Koinis F, Xagara A, Chantzara E, Leontopoulou V, Aidarinis C, Kotsakis A. Myeloid-derived suppressor cells in prostate cancer: present knowledge and future perspectives. Cells 2021;11:20\u201336.","DOI":"10.3390\/cells11010020"},{"key":"9098_CR47","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1158\/1078-0432.CCR-14-3145","volume":"21","author":"DM Hossain","year":"2015","unstructured":"Hossain DM, Pal SK, Moreira D, Duttagupta P, Zhang Q, Won H, et al. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clin Cancer Res. 2015;21:3771\u201382.","journal-title":"Clin Cancer Res"},{"key":"9098_CR48","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00262-014-1591-2","volume":"63","author":"M Idorn","year":"2014","unstructured":"Idorn M, K\u00f8llgaard T, Kongsted P, Sengel\u00f8v L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother. 2014;63:1177\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"9098_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19:108\u201319.","journal-title":"Nat Immunol"},{"key":"9098_CR50","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.molcel.2011.08.011","volume":"43","author":"ST Lee","year":"2011","unstructured":"Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, et al. Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol Cell. 2011;43:798\u2013810.","journal-title":"Mol Cell"},{"key":"9098_CR51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1101\/gad.1632208","volume":"22","author":"LA Puto","year":"2008","unstructured":"Puto LA, Reed JC. Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylation. Genes Dev. 2008;22:998\u20131010.","journal-title":"Genes Dev"},{"key":"9098_CR52","doi-asserted-by":"publisher","first-page":"27857","DOI":"10.1074\/jbc.M109.000950","volume":"284","author":"X Chen","year":"2009","unstructured":"Chen X, El Gazzar M, Yoza BK, McCall CE. The NF-kappaB factor RelB and histone H3 lysine methyltransferase G9a directly interact to generate epigenetic silencing in endotoxin tolerance. J Biol Chem. 2009;284:27857\u201365.","journal-title":"J Biol Chem"},{"key":"9098_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0447-9","volume":"15","author":"M Wang","year":"2018","unstructured":"Wang M, Yang W, Chen Y, Wang J, Tan J, Qiao W. Cellular RelB interacts with the transactivator Tat and enhance HIV-1 expression. Retrovirology. 2018;15:65.","journal-title":"Retrovirology"},{"key":"9098_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10735-015-9624-5","volume":"46","author":"T Ni","year":"2015","unstructured":"Ni T, Mao G, Xue Q, Liu Y, Chen B, Cui X, et al. Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis. J Mol Histol. 2015;46:325\u201335.","journal-title":"J Mol Histol"},{"key":"9098_CR55","doi-asserted-by":"crossref","unstructured":"Marchesini M, Ogoti Y, Fiorini E, Aktas Samur A, Nezi L, D\u2019Anca M, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell 2017;32:88\u2013100.","DOI":"10.1016\/j.ccell.2017.05.011"},{"key":"9098_CR56","volume":"2019","author":"H Du","year":"2019","unstructured":"Du H, Le Y, Sun F, Li K, Xu Y. ILF2 Directly Binds and Stabilizes CREB to Stimulate Malignant Phenotypes of Liver Cancer Cells. Anal Cell Pathol (Amst). 2019;2019:1575031.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"9098_CR57","doi-asserted-by":"publisher","first-page":"8142","DOI":"10.1038\/sj.onc.1204884","volume":"20","author":"R Marienfeld","year":"2001","unstructured":"Marienfeld R, Berberich-Siebelt F, Berberich I, Denk A, Serfling E, Neumann M. Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control. Oncogene. 2001;20:8142\u20137.","journal-title":"Oncogene"},{"key":"9098_CR58","doi-asserted-by":"publisher","first-page":"39242","DOI":"10.1074\/jbc.M301521200","volume":"278","author":"HJ Maier","year":"2003","unstructured":"Maier HJ, Marienfeld R, Wirth T, Baumann B. Critical role of RelB serine 368 for dimerization and p100 stabilization. J Biol Chem. 2003;278:39242\u201350.","journal-title":"J Biol Chem"},{"key":"9098_CR59","doi-asserted-by":"publisher","first-page":"14794","DOI":"10.1073\/pnas.1410124111","volume":"111","author":"H Authier","year":"2014","unstructured":"Authier H, Billot K, Derudder E, Bordereaux D, Riviere P, Rodrigues-Ferreira S, et al. IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors. Proc Natl Acad Sci USA 2014;111:14794\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9098_CR60","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1042\/BJ20080432","volume":"416","author":"J Leidner","year":"2008","unstructured":"Leidner J, Palkowitsch L, Marienfeld U, Fischer D, Marienfeld R. Identification of lysine residues critical for the transcriptional activity and polyubiquitination of the NF-kappaB family member RelB. Biochem J. 2008;416:117\u201327.","journal-title":"Biochem J"},{"key":"9098_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41388-021-02087-8","volume":"41","author":"HW Huang","year":"2022","unstructured":"Huang HW, Chen CY, Huang YH, Yeh CT, Wang CS, Chang CC, et al. CMAHP promotes metastasis by reducing ubiquitination of Snail and inducing angiogenesis via GM-CSF overexpression in gastric cancer. Oncogene. 2022;41:159\u201372.","journal-title":"Oncogene"},{"key":"9098_CR62","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cellimm.2012.02.012","volume":"274","author":"HC Zhu","year":"2012","unstructured":"Zhu HC, Qiu T, Liu XH, Dong WC, Weng XD, Hu CH, et al. Tolerogenic dendritic cells generated by RelB silencing using shRNA prevent acute rejection. Cell Immunol. 2012;274:12\u201318.","journal-title":"Cell Immunol"},{"key":"9098_CR63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cellimm.2013.03.004","volume":"282","author":"L Luo","year":"2013","unstructured":"Luo L, Sun Z, Fang Q, Huang S, Bai X, Luo G. Effects of tolerogenic dendritic cells generated by siRNA-mediated RelB silencing on immune defense and surveillance functions of T cells. Cell Immunol. 2013;282:28\u201337.","journal-title":"Cell Immunol"},{"key":"9098_CR64","doi-asserted-by":"publisher","first-page":"7688","DOI":"10.1128\/MCB.19.11.7688","volume":"19","author":"Y Xia","year":"1999","unstructured":"Xia Y, Chen S, Wang Y, Mackman N, Ku G, Lo D, et al. RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta, and tumor necrosis factor alpha in fibroblasts. Mol Cell Biol. 1999;19:7688\u201396.","journal-title":"Mol Cell Biol"},{"key":"9098_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70058","volume":"14","author":"W Sun","year":"2024","unstructured":"Sun W, Xu K, Li X, Qian P, Xu F, Zhang Y, et al. Insight into prostate cancer osteolytic metastasis by RelB coordination of IL-8 and S100A4. Clin Transl Med. 2024;14:e70058.","journal-title":"Clin Transl Med"},{"key":"9098_CR66","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1158\/0008-5472.CAN-08-4635","volume":"69","author":"Y Xu","year":"2009","unstructured":"Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, et al. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res. 2009;69:3267\u201371.","journal-title":"Cancer Res"},{"key":"9098_CR67","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15:2148\u201357.","journal-title":"Clin Cancer Res"},{"key":"9098_CR68","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","volume":"23","author":"N Agarwal","year":"2022","unstructured":"Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022;23:899\u2013909.","journal-title":"Lancet Oncol"},{"key":"9098_CR69","doi-asserted-by":"crossref","unstructured":"DeNardo DG, Galkin A, Dupont J, Zhou L, Bendell J. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. J Immunother Cancer. 2021;9:e003005.","DOI":"10.1136\/jitc-2021-003005"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09098-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09098-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:03:45Z","timestamp":1791263025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09098-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9098"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09098-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All experimental procedures were conducted in accordance with relevant guidelines and regulations. Animal experiments were approved by the Institutional Animal Care and Use Committee of Nanjing Medical University (Approval No. IACUC-2011014). Human tissue collection and analysis were approved by the Ethics Committee of Nanjing Medical University (Approval No. 2021-521). Written informed consent was obtained from all participants prior to sample collection.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"863"}}